Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead ...

U.S. stocks on Wednesday slipped, as investors digested a slight acceleration in the Federal Reserve's favorite inflation gauge. Here are some of Wednesday's biggest stock movers: Biggest stock ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

RBC Capital analyst Luca Issi maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price target of ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference ...

Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics. Their proprietary platform, Targeted RNAi Molecule (TRiM™), allows them to target and ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

Arrowhead Pharmaceuticals (ARWR) stock surges 21% in premarket after $825M licensing deal with Sarepta (SRPT) for rare ...

US companies Arrowhead Pharmaceuticals (Nasdaq: ARWR) and Sarepta Therapeutics (Nasdaq: SRPT) have announced a global licensing and collaboration agreement. Shares in Arrowhead were 17% higher early ...

Analysts estimate that Arrowhead Pharma will report an earnings per share (EPS) of $-1.05. The market awaits Arrowhead Pharma's announcement, with hopes high for news of surpassing estimates and ...